



NDA 021324/S-023

## **SUPPLEMENT APPROVAL**

Perrigo Pharma International DAC  
Attention: Jocelyn Clark-Greuel, Ph.D.  
Associate Director, Regulatory Affairs  
3940 Quebec Avenue North  
Minneapolis, MN 55427

Dear Dr. Clark:

Please refer to your supplemental new drug application (sNDA) dated March 13, 2020, received March 13, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Entocort EC (budesonide) delayed-release capsules.

This Prior Approval supplemental new drug application provides for changes to the dosage form nomenclature (“delayed-release capsules”) throughout labeling and inclusion of pharmacokinetic data in Section 12.3 Clinical Pharmacology of the Prescribing Information.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

- Updated the revision date at the end of Highlights and at the end of the Full Prescribing Information to the approval date. Also, update the revision date at the end of the Patient Package Insert.
- Moved the heading “DOSAGE FORMS AND STRENGTHS” from the end of the first column to the top of the second column in Highlights.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert), with the addition of any labeling

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELING**

We acknowledge your March 13, 2020, submission containing final printed carton and container labeling with minor editorial revision to update the revision date to the approval date.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

If you have any questions, contact Andrew Kelleher, Ph.D., Regulatory Project Manager, at (301) 796-9330 or email [andrew.kelleher@fda.hhs.gov](mailto:andrew.kelleher@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Jessica J. Lee, M.D., M.M.Sc.  
Director (Acting)  
Division of Gastroenterology  
Office of Immunology and Inflammation  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
  - Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JESSICA J LEE  
07/15/2020 09:41:44 AM